retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 is a triple-agonist drug targeting GLP-1, GIP, and receptors to suppress appetite and boost thermogenesis. trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing GLP-1 Medications for Weight Loss:

Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke

Low- and middle-income countries demonstrate rapid growth of type 2 diabetes: an analysis based on Global Burden of Disease 19902019 data

But there was a clear consensus among experts at the ASAM conference: more research is needed

86 Finally, patients taking GLP-1RAs reduce caloric intake by 16%-39%, with some reporting 35%-40% reduction in high-fat food, 12.2% reduction in carbohydrate intake, and significant decreases in cravings for salty, spicy, dairy, and starchy foods

GLP-1 Drugs Affect Your Gut and Brain These medications also enhance insulin secretion, which can result in better blood sugar control in addition to weight loss, says Sara Velayati, MD, an obesity medicine specialist at Montefiore Einsteins Fleischer Institute Medical Weight Center in New York

Saxenda is FDA-approved for chronic weight management, while Ozempic is used for Type 2 diabetes in adults